Download Rolf Craven-cv - Pharmacology and Nutritional Sciences

ROLF JOSEPH CRAVEN
2429 Woodfield Circle
Lexington, Kentucky 40515
Phone (859) 245-4108
Office address:
University of Kentucky
Department of Molecular and Biomedical Pharmacology
213 Combs Building, Markey Cancer Center
Lexington, Kentucky 40536
Phone (859) 323-3832
FAX (859) 257-9608
e-mail [email protected]
Education:
B.S. Biochemistry
M.S. Biochemistry
Ph.D. Genetics
Professional experience:
Research Analyst
Post-doctoral fellow
Assistant Professor
Assistant Professor
Associate Professor
Vice-Chair, IRB
Scientific Advisory Board
Faculty Member
Clemson University
University of IllinoisChicago Health Sci. Center
University of North
Carolina-Chapel Hill
Clemson, S.C.
April, 1985
Chicago, Ill.
December, 1987
(Mentor: Dr. Stephen S. Chung)
Chapel Hill, N.C.
December, 1996
(Mentor: Dr. Edison T. Liu)
UNC-Chapel Hill
Chapel Hill, NC
8/1990-8/1993
Department of Surgery, Lineberger Cancer Center
UNC-Chapel Hill
Chapel Hill, NC
8/1996-12/2000
Department of Biology (Dr. Thomas Petes, member Natl. Acad. Sci.)
UNC-Chapel Hill
Chapel Hill, NC
1/2001-6/2003
Department of Surgery, Division of Surgical Oncology
University of Kentucky
Lexington, Ky.
7/2003-present
Department of Molecular and Biomedical Pharmacology
University of Kentucky
Lexington, Ky.
5/2009-present
Department of Molecular and Biomedical Pharmacology
University of Kentucky
Lexington, Ky.
6/2013-present
Cognition Therapeutics, Inc. Pittsburgh, PA.
6/2013-present
University of Kentucky
Lexington, Ky.
6/2013-present
Graduate Center for Nutritional Sciences
Areas of expertise:
Development of experimental therapeutics/target identification and validation
Receptor-mediated and intracellular signaling in proliferation, survival, and adhesion
Mechanisms of apoptosis and resistance in cancer cells
Gene expression and manipulation in clinical tumor samples and tumor cell lines
Awards:
2007
2006
2004
2001-3/2007-8
Wethington Award for research from the University of Kentucky
Wethington Award for research from the University of Kentucky
Wethington Award for research from the University of Kentucky
Scholar of the B.I.R.C.W.H. Program (Building Interdisciplinary
Research Careers in Women’s Health) from the N.I.H.
1
1997-2000
1996
Post-doctoral fellowship from the American Cancer Society. "Biological
functions of the ATM-related gene TEL1
Rhone-Poulenc Travel Award for the 87th Annual Meeting of the
American Association of Cancer Research. Washington, D.C.
Publications:
Mir, S.U.R., Schwarze, S., Jin, L., Zhang, J. Friend, W., Miriyala, S., St Clair, D. and Craven, R.J.
Sigma-2 receptor associates with MAP1-LC3B and promotes autophagy. Autophagy, in press.
Jin, L. and Craven R.J. The Rak/Frk tyrosine kinase associates with and internalizes the epidermal
growth factor receptor. Oncogene, in press.
Breuer, E.-K. Y., Murph, M.M. and Craven, R.J. Biochemical Pathways in Cancer. Biochemistry
Research International. 2012: 268504 (2012).
Mir, S.U.R., Jin, L. and Craven, R.J. Ngal (neutrophil gelatinase-associated lipocalin) transcription
dependent on the tumor-associated sigma-2 receptor S2RPgrmc1. Journal of Biological Chemistry,
287: 14494-14501 (2012).
Ahmed, I.S., Chamberlain, C. and Craven, R.J. S2RPgrmc1: the cytochrome-related sigma-2 receptor
that regulates lipid and drug metabolism and hormone signaling. Expert Opinion on Medicinal
Chemistry and Toxicology, 8: 361-370 (2012).
Mir, S.U.R., Ahmed, I.S., Arnold, S. and Craven, R.J. Elevated Pgrmc1 (progesterone receptor
membrane component 1)/sigma-2 receptor levels in lung tumors and plasma from lung cancer
patients. International Journal of Cancer 131: 1-9 (2011).
Mallory, J.C. and Craven, R.J. Candida albicans Dap1p promotes ergosterol synthesis via the P450
protein Erg11p/Cyp51p, regulating susceptibility to azole antifungal drugs, morphogenesis and
damage resistance. Pharmacologia 3: 179-189 (2011).
Ahmed, I.S., Rohe, H.J., Twist, K.E. and Craven, R.J. Pgrmc1 (progesterone receptor membrane
component 1) associates with EGFR and regulates erlotinib sensitivity, Journal of Biological
Chemistry, 285: 24775-24782 (2010).
Ahmed, I.S, Rohe, H.A., Twist, K., Mattingly, M. and Craven, R.J. Pgrmc1 (progesterone receptor
membrane component 1): a heme-1 domain protein that promotes tumorigenesis and is inhibited
by a small molecule. Journal of Pharmacology and Experimental Therapeutics, 333: 564-573
(2010).
Dietrich CS, Greenberg VL, DeSimone CP, Modesitt SC, van Nagell JR, Craven R., Zimmer SG.
Suberoylanilide Hydroxamic Acid (SAHA) Potentiates Paclitaxel-Induced Apoptosis in Ovarian
Cancer Cell Lines. Gynecologic Oncology, 116: 126-130 (2010).
Yim, E.-Y., Peng, G., Dai, H., Hu, R., Li, K., Lu, Y., Mills, G.B., Meric-Bernstam, F., Hennessy, B.T.,
Craven, R.J. and Lin, S.-Y. Rak functions as a tumor suppressor by regulating PTEN protein
stability and function. Cancer Cell, 15: 304-314 (2009).
Craven, R.J., Rohe, H.A., Ahmed, S.A. and Twist, K. The PGRMC1 protein family: targetable
receptor/co-activator proteins linking steroid hormone signaling to P450 activation. Pharmacology
and Therapeutics 121: 14-29 (2009)
Yang, M.M., Jarrett, S., Craven, R.J. and Kaetzel, D.M. YNK1, the yeast homolog of human
metastasis suppressor NM23, is required for repair of UV radiation- and etoposide-induced DNA
damage. Mutation Research, 660: 74-79 (2009).
Craven, R.J. PGRMC1: a new biomarker for estrogen-responsive breast cancers. Breast Cancer
Research, 10: 113-114 (2008).
Craven, R.J., Mallory, J.C., and Hand, R.A. Regulation of iron homeostasis mediated by the hemebinding protein Dap1 (damage resistance protein 1) via the P450 protein Erg11/Cyp51. Journal of
Biological Chemistry 282: 36543-36551 (2007).
2
Ranney, M.K., Ahmed, I.A., Potts, K.R. and Craven, R.J. Multiple pathways regulating the antiapoptotic protein clusterin in breast cancer. Biochimica and Biophysica Acta 1772: 1103-11
(2007).
Kaetzel, D.M., Zhang, Q., Yang, M., McCorkle, J.R., Ma, D., and Craven, R.J. Potential roles of 3’-5’
exonuclease activity of NM23-H1 in DNA repair and malignant progression. J. Biomembranes
and Bioenergetics 38: 163-167 (2006).
Crudden, G., Smalley, R., and Craven, R.J. Hpr6 (heme-1 domain protein) regulates the susceptibility
of cancer cells to chemotherapeutic drugs. Journal of Pharmacology and Experimental
Therapeutics 316: 448-455 (2006).
Mallory, J.C., Crudden, G., Oliva, A., Saunders, C., Stromberg, A., and Craven, R.J. A novel group of
genes associated with survival in breast cancer cells treated with anti-neoplastic drugs. Molecular
Pharmacology 68: 1748-1757 (2005).
Mallory, J.C., Crudden, G., Johnson, B.L., Mo, C., Pierson, C.A., Bard, M., and Craven, R.J. Dap1p:
a heme-binding protein that regulates the cytochrome P450 protein Erg11p/Cyp51p in
Saccharomyces cerevisiae. Molecular and Cellular Biology, 25: 1669-1679 (2005).
Crudden, G., Lösel, R., and Craven, R.J. Overexpression of the cytochrome P450 activator Hpr6
(heme-1 domain protein/human progesterone receptor) in tumors. Tumor Biology, 26: 142-146
(2005).
Park, H.B., Golubovskaya, V.M., Xu, L., Yang, X., Lee, J.W., Scully, S., Craven, R.J., and Cance,
W.G. Activated Src elevated adhesion, survival and alpha-2 integrin expression in human breast
cancer cells. Biochemical Journal, 378: 559-567 (2004).
Kurenova, E., Xu, L.-H., Yang, X., Baldwin, A.S., Craven, R.J., Hanks, S.K., Liu, Z.-G., and Cance,
W.G. Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor
interacting protein. Molecular and Cellular Biology, 24: 4361-4371 (2004).
Hand, R.A., Jia, N., Bard, M.A., and Craven, R.J. Saccharomyces cerevisiae Dap1p, a novel DNA
damage response protein related to the mammalian membrane-associated progesterone receptor.
Eukaryotic Cell 2: 121-132 (2003).
Craven, R.J.* and Cance, W.G. A decade of tyrosine kinases: from gene discovery to therapeutics.
Surgical Oncology 12: 39-49 (2003). *corresponding author.
Yang, X..H., Hand, R.A., Livasy, C.A., Cance, W.G., and Craven, R.J. Overexpression of the receptor
tyrosine kinase tie-1 intracellular domain in breast cancer. Tumor Biology 24: 61-69 (2003).
Hand, R.A. and Craven, R.J. The Hpr6.6 protein mediates cell death from oxidative damage in MCF7 human breast cancer cells. Journal of Cellular Biochemistry, 90: 534-547 (2003).
Meyer, T., Xu, L., Chang, J., Liu, E.T., Craven, R.J., and Cance, W.G. The Rak tyrosine kinase
inhibits growth of human breast cancer cells. International Journal of Cancer 104: 139-146
(2003).
Beviglia, L., Golubovskaya, V., Xu, L., Yang, X., Craven, R.J., and Cance, W.G. The focal adhesion
kinase amino-terminal domain induces loss of adhesion and apoptosis in breast carcinoma cells.
Biochemical Journal 373: 201-210 (2003).
Craven, R.J., Greenwell, P.W., Dominska, M., and Petes, T.D. Control of genetic stability by the
Saccharomyces cerevisiae kinases Mec1p and Tel1p. Genetics 161: 493-507 (2002).
Golubovskaya, V., Beviglia, L., Xu, L., Earp, H.S., Craven, R., and Cance, W. Focal Adhesion Kinase
(FAK) and Epidermal Growth Factor Receptor (EGFR) synergistically suppress death receptormediated apoptosis in human breast cancer cells by activating Akt and Erk 1 and 2 signaling
pathways. Journal of Biological Chemistry 277: 38978-38987 (2002).
Craven, R.J., and Petes, T.D. The Saccharomyces cerevisiae Suppressor of Choline Sensitivity
(SCS2) gene is a multicopy suppressor of mec1 telomeric silencing defects. Genetics 158: 145-154
(2001).
3
Xu, L.-H., Yang, X., Bradham, C.A., Brenner, D.A., Baldwin, A.S., Craven, R.J., and Cance, W.G.
The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis
in human breast cancer cells. Journal of Biological Chemistry 275: 30597-30604 (2000).
Craven, R.J., and Petes, T.D. Involvement of the checkpoint protein Mec1p in silencing of gene
expression at telomeres in Saccharomyces cerevisiae. Molecular and Cellular Biology, 20: 23782384 (2000).
Craven, R.J., and Petes, T.D. Dependence of the regulation of telomere length on the type of subtelomeric repeat in the yeast Saccharomyces cerevisiae. Genetics 152: 1531-1541 (1999).
Xu, L.H., Yang, X., Craven, R.J., and Cance, W.G. The COOH-terminal domain of the focal
adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth &
Differentiation 9: 999-1005 (1998).
Owens, L.V., Xu, L., Dent, G.A., Yang, X., Sturge, G.C., Craven, R.J., and Cance, W.G. The focal
adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Annals
of Surgical Oncology 3: 100-105 (1996).
Xu, L., Owens, L.V., Sturge, G.C., Yang, X., Liu, E.T., Craven, R.J., and Cance, W.G. Attenuation
of the Expression of the Focal Adhesion Kinase Induces Apoptosis in Tumor Cells. Cell Growth
& Differentiation 7: 413-418 (1996).
Craven, R.J., Cance, W.G., and Liu, E.T. The nuclear tyrosine kinase Rak associates with the product
of the Retinoblastoma tumor susceptibility gene, pRb. Cancer Research, 55: 3969-3972 (1995).
Craven, R.J., Xu, L., Weiner, T.M., Fridell, Y.-W., Dent, G.A., Srivastava, S., Varnum, B., Liu, E.T.,
and Cance, W.G. Receptor tyrosine kinases expressed in metastatic colon cancer. International
Journal of Cancer 60: 791-797 (1995).
Owens L.V., Xu, L., Craven, R.J., Dent, G.A., Weiner, T.M., Kornberg, L., Liu, E.T., and Cance,
W.G.Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer
Research 55: 2752-2755 (1995).
Cance, W.G., Craven, R.J., Bergman, M., Xu, L., Alitalo, K., and Liu, E.T. Rak, a novel nuclear
tyrosine kinase expressed in epithelial cells. Cell Growth and Differentiation 5: 1347-1355 (1994).
Craven, R.J. and Cance, W.G. Protein tyrosine kinases in the early detection of colorectal cancer. In
“Early detection of cancer: molecular markers” Eds. Srivastava, S., Lippman, S.M., Hong, WK,
and Mulshine, J.L. Armonk: Futura Publishing Co., Inc., 1994.
Levedakou, E.N., He, M., Baptist, E.W., Craven, R.J., Cance, W.G., Welcsh, P.L., Simmons, A.,
Naylor, S.L., Leach, R.J., Lewis, T.B., Bowcock, A., and Liu, E.T. Two novel human
serine/threonine kinases with homologies to the cell cycle regulating Xenopus MO15, and NimA
kinases: cloning and characterization of their expression pattern. Oncogene 9: 1977-1988 (1994).
Weiner, T.M., Liu, E.T., Craven, R.J., and Cance, W.G. Expression of growth factor receptors, the
focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors. Annals of Surgical
Oncology 1: 18-27 (1994).
Weiner, T.M., Liu, E.T., Craven, R.J., and Cance, W.G. Expression of focal adhesion kinase gene
and invasive cancer. Lancet 342: 1024-1025 (1993).
Cance, W.G., Craven, R.J., Weiner, T.M., and Liu, E.T. Novel protein kinases expressed in human
breast cancer. International Journal of Cancer 54: 571-577 (1993).
Cance, W.G., Craven, R.J., and Liu, E.T. Expression polymerase chain reaction: a sensitive method
for analysis of gene expression in human tumors. Surgical Oncology 1: 309-314 (1992).
Meetings (only selected abstracts since beginning at U.Ky. are shown):
Mir, S.U.R., Jin, L. and Craven, R.J. Elevated sigma-2 receptor/Pgrmc1 (progesterone receptor membrane
component 1) levels as a potential cancer biomarker in tumors and plasma. American Association for
Cancer Research Annual Meeting. Chicago, Illinois, April, 2012.
4
Mir, S.U.R., Jin, L. and Craven, R.J. “Ngal (neutrophil gelatinase-associated lipocalin) transcription
dependent on the tumor-associated cytochrome Pgrmc1” American Association for Cancer
Research meeting on Metabolism and Cancer. Baltimore, Maryland, October 16-19, 2011.
Craven RJ, Ahmed IS, Rohe HJ, Twist K and Kim JA. “Pgrmc1: a tumor-associated cytochrome and
therapeutic target for cancer.” Conference of the Molecular Therapeutics of Cancer Research
Association. Princeton University, Princeton, New Jersey, July 18, 2010.
Ahmed IS, Rohe HJ, Twist KR, Kim JA and Craven RJ. “Pgrmc1 associates with EGFR in the
endoplasmic reticulum lumen to promote lung cancer growth and metastasis.” Kentucky Lung
Cancer Research Program Annual Meeting. Lexington, Kentucky, March 25, 2010.
Ahmed IS, Rohe HJ, Twist KR, Kim JA and Craven RJ. “Pgrmc1 promotes NSCLC migration,
survival and tumor growth and associates with EGFR” Kentucky Lung Cancer Research Program
Annual Meeting. Louisville, Kentucky, November 14, 2009.
Ahmed IS, Twist KE, Rohe HJ and Craven RJ. A novel pathway regulates EGFR (epidermal growth
factor receptor) stability in cancer cells. Cold Spring Harbor Laboratory Meeting on
Phosphorylation and Disease. Cold Spring Harbor, New York. May 8, 2009.
Craven, R.J., Ahmed, I., Mallory, J.C. and Rohe, H. The PGRMC1/Dap1 protein family: P450binding proteins that regulate P450 stability. 2008 Southwest Cytochrome P450 Meeting. Camp
Allen, Texas. May 12, 2008. R.C. was an invited speaker.
Ahmed, IA, Condley, CA and Craven, RJ. PGRMC1/Dap1: a novel family of P450 activators related
to cytochrome b5. Ohio Valley Society of Toxicology Annual Meeting. Indianapolis, IN.
November 2, 2007. I.A. was an invited speaker.
Mallory, JM, Raymer, S, and Craven, RJ. Candida albicans Dap1 activates Erg11 and regulates
antifungal drug resistance. 47th Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC). Chicago, IL. September 17-20, 2007.
Mallory, JC, Hand, RA and Craven, RJ. Dap1p, a Saccharomyces cerevisiae protein that regulates
resistance to azole drugs and the DNA damaging agent MMS. 13th Annual Midwest Microbial
Pathogenesis Conference. Cincinnati, OH. October 21, 2006.
Craven RJ, Ranney M, and Ahmed I. The anti-apoptotic protein clusterin is induced by
chemotherapy, stabilized by the proteasome, and degraded by intracellular proteases. American
Association for Cancer Research meeting on molecular diagnostics in cancer therapeutic
development. Chicago, IL. September 12-15, 2006.
Ahmed I, Ranney M, and Craven RJ. Clusterin is induced by cancer chemotherapy and suppresses
histone deacetylase inhibitor-induced apoptosis in breast cancer. American Association for
Cancer Research meeting on molecular diagnostics in cancer therapeutic development. Chicago,
IL. September 12-15, 2006.
Craven RJ and Crudden G. The Hpr6.6 protein is overexpressed in human tumors and functions as a
survival signal. Annual meeting of the American Association for Cancer Research. Orlando, FL.
April 2, 2004.
Craven RJ, Crudden G, and Johnson, BL. Hpr6 (heme-1 domain protein): a novel chemotherapy
resistance protein overexpressed in human cancer cells. Sixth Annual Midwest DNA repair
symposium. Lexington, Ky. June 2004.
Invited seminars:
University of Cincinnati, hosted by the Department of Environmental Sciences. The seminar was
entitled, “A novel pathway regulates EGFR (epidermal growth factor receptor) function in cancer
cells.” April 7, 2010.
5
University of Miami-Ohio, hosted by the Department of Biology and Zoology. The seminar was
entitled, “A novel pathway regulates EGFR (epidermal growth factor receptor) function in cancer
cells.” September 17, 2009.
Wright State University, hosted by the Department of Pharmacology and Toxicology. The seminar
was entitled, “Pgrmc1: a cytochrome-related membrane signaling activator induced in cancer
cells”. March 5, 2009.
Vanderbilt University, hosted by the Department of Biochemistry. The seminar was entitled,
“Dap1/PGRMC1: conserved P450 activators that link cholesterol synthesis and cancer
therapeutics”. October 24, 2008.
Duke University, “The Thursday Series”, co-hosted by the Department of Cell Biology, the
Department of Molecular Genetics and Microbiology and the Cell and Molecular Biology
Program. The title of the seminar was “Conserved P450 activators that link cholesterol synthesis
and cancer therapeutics”. June 5, 2008.
Indiana University-Purdue University at Indianapolis, Department of Biology. The seminar was
entitled, “Dap1 and Hpr6: novel activators of cytochrome P450 proteins”. November 17, 2004.
Patent:
U.S. patent number 7342100, “Hpr6 mutants and uses thereof”, patents the use of Hpr6/Pgrmc1
mutants to sensitize cancer cells to chemotherapy.
Patent application pending, “A secreted tumor-associated cytochrome as a blood-based biomarker for
cancer” protects the discovery of Pgrmc1 as a plasma-based biomarker for cancer.
Teaching:
Course director: PHA622, Systems Pharmacology
Additional lectures:
Course:
Systems Pharmacology
Dental Pharmacology
Course #:
PHA622
OBI836
Medical Pharmacology
PHA824
Cancer Biology
Genetics
Cell Biology
IBS616
IBS605
IBS603
Subject of lectures:
Respiratory and Gastrointestinal drugs
Cancer chemotherapy, antifungal drugs and antituberculosis drugs
Antifungal drugs, gastrointestinal drugs, antihistamines,
anti-tuberculosis drugs, cancer chemotherapy, gene
therapy, treatment of anemia
Telomeres, telomerase, and aging
Genetic analysis in yeast
Molecular basis of cancer
Guest lecturer: Transylvania University, Senior Microbiology Course, April 2007
Past/current undergraduate, graduate and medical students:
Ikhlas Said Ali Ahmed, graduate student, Pharmacology
Cora Chamberlain, Research project as undergraduate, 2011
Rachel Edwina Chitti, Master’s degree in Pharmacology
Clay Adams Condley, medical student, did research as M2
6
Woodrow Friend, Graduate student, Pharmacology
Ji Ae Kim, Research project as undergraduate student, enrolled in UKy School of Pharmacy 2011
Julia Mallory, Post-doctoral fellow
Shakeel Mir, Post-doctoral fellow
Kelly Potts, medical student, did research as M1
Melissa Ranney, medical student, did research as M2
Hannah Rohe, medical student, did research as M1
Katie Twist, medical student, did research as M2
University service:
Chair, Recruitment Committee for Director of Clinical Pharmacology, College of Medicine, 2013
Member, Faculty Recruitment Committee for Department of Molecular and Biomedical
Pharmacology, three tenure-track faculty positions, 2013
Member, Institutional Review Board (IRB), 2011-present
Vice-Chair, Institutional Review Board, 2013-present
Member, College of Medicine Curriculum sub-committees: Foundations of Basic Science Committee,
2011-present
Member, College of Medicine Curriculum sub-committees: Lymph Node/Marrow/Blood Committee,
2011-present
Member, College of Medicine Integrated Biomedical Sciences Curriculum Revision Task Force, 2011present
Member, Markey Research Conference Advisory Committee, 2008-2011
Member, Admissions Committee, Integrated Biomedical Sciences Curriculum, 2007-2011
Member, American Cancer Society Institutional Research Grant Oversight Committee, 2008-2011
Judge, U. Ky. School of Medicine Post-doctoral Research Day
Member, Graduate Education Steering Committee, Department of Molecular and Biomedical
Pharmacology, 2007-present
Director, IBS student orientation for the Pharmacology Department, 2007-2011
Reviewer, Project grant, Marty Driesler Cancer Project
Reviewer, Project grant, Markey Cancer Center
Reviewer, Pilot grant project, University of Kentucky Research Foundation
Doctoral thesis committee member for the following current graduate students:
Lin Ao, Pharmaceutical Sciences
Tripti Bhattarai, Toxicology
Leann Fiore, Pharmacology
Anwesha Goswami, Pharmaceutical Sciences
SangHee Lee, Nutrition Sciences
Xiaobo Li, Biochemistry
Cassandra Reiling, Toxicology
Jason Tucker, Pharmacology
Doctoral thesis committee member for the following former graduate students:
Ikhlas Ahmed, Pharmacology
Meng Meng Cheng, Pharmacology
Rachel Smalley Chitti, Pharmacology
Kedra Cyrus, Pharmacy
Aubrey Franz, Microbiology and Molecular Genetics
Brock Howerton, Chemistry
7
Xiuling Li, College of Pharmacy
Enerlyn Lozada, Toxicology
Michelle Olson, Pharmacology
Dinesh Puppula, Pharmacology
Timothy Scott, Toxicology
Jonathan Sims, Pharmacology
Yolanda Williams, Pharmacy
Katerina Zaytseva, Pharmacology
Advisor for the following Integrated Biomedical Sciences rotation students:
Chirie Sumanasekera
Megan Sampley
Janine Owens
Lesley Gilmer
Angie Martin
Rachel Smalley
Brandon Adkins
Ikhlas Said Ali Ahmed
Lorenzo Federico
Matthew Thacker
Memberships:
American Association for Cancer Research
American Society for Microbiology
American Society for Pharmacology and Experimental Therapeutics
American Society for Biochemistry and Molecular Biology
Ohio Valley Society of Toxicology
Extramural study section:
Department of Defense- CDMRP- Scientist Reviewer- Clinical and Experimental Therapeutics A2010-present
American Institute for Cancer Research- Ad hoc reviewer 2012
Dutch Cancer Society- Ad hoc reviewer- 2012
Reviewer for the following journals:
Biochemistry
Editorial Board, Biochemistry Research International
Breast Cancer Research
British Journal of Cancer
Cellular and Molecular Life Sciences
Chemistry and Biology (Cell press)
Comparative Hematology
Eukaryotic Cell
European Journal of Biochemistry
International Journal of Cancer
Journal of Pharmacology and Experimental Therapeutics
Journal of Biological Chemistry
8
Molecular and Cellular Biology
Molecular and Cellular Endocrinology
Molecular Pharmacology
PLOS One
Tissue Antigens
Research support
Current:
“Stable isotope-derived metabolomics to elucidate the mechanism of a tumor-associated cytochrome in
lung cancer growth and metabolism”
Role: Project P.I.
Agency: KLCR
Type: Research award
Period: 12/1/2010-11/30/2012
The goals of the project are to determine the role of the cytochrome Pgrmc1 in regulating glycolysis
and hypoxia-associated metabolism in lung cancer.
“Novel small molecule inhibitors targeting cancer growth via EGFR”
Rolf: Project P.I.
Agency: KSEF-09-RDE-013 research grant
Period: 8/1/2010-7/30/2012
The goals of the project are to determine the extent to which Ero1 and Pgrmc1 regulate EGFR folding
and to develop and test new inhibitors for Pgrmc1.
“S2RPgrmc1: sigma-2 receptor as a therapeutic target in lung cancer”
Role: Project P.I.
Agency: Bonnie J. Addario Lung Cancer Research Foundation
Period: 1/1/2012-12/31/2013
The goals of the project are to determine the extent to which secreted S2RPgrmc1 acts as a prognostic
indicator for resistance to EGFR inhibitors.
“A stem cell biomarker and therapeutic target in Appalachian lung cancer”
Role: co-PI
Agency: University of Kentucky Clinical Center for Translational Research
Period: 3/1/2012-2/28/2013
The goals of the project are to isolate stem cells from clinical lung tumors at Marshall University,
analyze them for S2R levels and test their sensitivity to S2R inhibitors.
Pending:
“Pre-clinical and clinical chemotherapy with taxanes and sigma-2 receptor inhibitors”
Role: Project P.I.
Agency: KLCR
Type: Research award
Period: 5/1/2012-4/30/2014
The goals of the project are to determine the activity of sigma-2 receptor inhibitors combined with
standard chemotherapy against lung cancer in cell line and animal models.
Completed:
“Signaling from receptor tyrosine kinases to PTEN in lung cancer”
Role: Project P.I.
Agency: KLCR
Type: Research award
Period: 11/1/2009-10/31/2011
The goals of the project are to determine the extent to which the intracellular Rak tyrosine kinase is
inhibited by receptor tyrosine kinases, de-stabilizing the tumor suppressor PTEN.
9
“A novel approach for targeting the epidermal growth factor receptor (EGFR) in lung cancer”
Role: Project P.I.
Agency: KLCR
Type: Research grant
Period: 1/1/2009-12/31/2010
The goals of the project are to perform pre-clinical tests with a novel Pgrmc1 inhibitor that destabilizes the receptor tyrosine kinase EGFR in lung cancer cells and to test the correlation between
EGFR and Pgrmc1 in expression in clinical lung cancer samples.
“A novel activator of Cyp19/aromatase induced in human breast cancer cells”
Role: project P.I.
Agency: ACS
Type: 85-001-19-IRG
Period: 1/1/2008-12/31/2009
The primary aim of the project is to test the extent to which PGRMC1 (progesterone receptor
membrane component 1) binds and activates the P450 protein Cyp19/aromatase.
“Gender differences in the metabolism of addictive drugs via P450 protein activation”
Role: Scholar
Agency: NIH/NIGMS
Type: BIRCWH P20 RR 15592
Period: 9/1/2007-8/31/2008
The major goal of the project is to determine the extent to which PGRMC1 is induced differentially by
certain addictive drugs, altering their metabolism.
“Clusterin splice variants in chemotherapy resistance”
P.I.: Craven
Agency: ACS
Type: 85-001-19-IRG
Period: 1/1/2006-12/31-2007
The primary aim of the project is to analyze the synthesis and function of a nuclear isoform of clusterin
in breast cancer cells treated with the chemotherapeutic agent doxorubicin.
“Hpr6 (heme-1 domain protein): a novel regulator of progesterone and estrogen action”
P.I.: Craven
Agency: NIH/NIGMS
Type: COBRE P20 RR 15592
Period: 7/1/2004-4/30/2007
The major goal of the project is to determine the extent to which Hpr6 (an activator of P450 proteins)
regulates the synthesis and signaling function of steroid hormones.
“Yvh1p, a regulator of Mec1p telomere signaling”
P.I.: Craven
Agency: NIH/NIA
Type: 1 R03 AG022700-01
Period: 7/1/2003-6/31/2004
The major goals of the project are to analyze the function of the Yvh1p phosphatase as a negative
regulator of the Atm-related kinase Mec1p.
“Hpr6, a cytochrome b5-related stress protein”
P.I.: Orringer
Agency: NIH/NICHD
Type: 1 K12 HD001441
Period: 4/1/2001-4/30/2003
This was a junior faculty training grant in which the role of Hpr6 in breast cancer progression and in
oxidative stress was analyzed.
“The role of the Atm-related TEL1 gene in telomere maintenance”
P.I.: Craven/Petes
Agency: ACS
Type: PF-4435 (post-doctoral)
Period: 4/1/1997-3/30/2000
The major goals of the project were to analyze the genetic pathway regulated by the Saccharomyces
cerevisiae TEL1 gene in regulating chromosome structure and telomere length maintenance.
10
“The biological role of the Rak tyrosine kinase in breast cancer”
P.I.: Craven/Liu
Agency: DOD
Type: DAMD17-96-6068 (pre-doc) Period: 6/1/1995-12/31/1996
The major goals of the project were to analyze the binding partners of the Src-related Rak tyrosine
kinase in human breast cancer cells.
11